Real-world overall survival (OS) improvements in metastatic urothelial carcinoma (mUC) across three key therapeutic eras.Antonio Cigliola, Andrea Necchi, N. Agarwal et al.|Journal of Clinical Oncology|2026Cited by 1
<i>ERBB3</i> -altered clinically advanced urothelial bladder cancer: Genomic landscape study and therapeutic possibilities.Steven Blinka, Petros Grivas, Roger Li et al.|Journal of Clinical Oncology|2026Cited by 0
Homologous recombination deficiency signature (HRDsig) status in <i>BRCA1/2</i> wild type ( <i>BRCA1/2</i> wt) clinically advanced prostate cancer (CAPC).Georges Gebrael, Neeraj Agarwal, Gennady Bratslavsky et al.|Journal of Clinical Oncology|2026Cited by 0
Relapsed/refractory clinically advanced (CA) testicular non-seminomatous germ cell tumors (NSGCT): A genomic landscape study.Valentina Tateo, Andrea Necchi, Gennady Bratslavsky et al.|Journal of Clinical Oncology|2026Cited by 0
<i>MTAP</i> loss in penile squamous cell carcinoma (penSCC): A genomic landscape study.Eyal Kord, Philippe Edouard Spiess, Gennady Bratslavsky et al.|Journal of Clinical Oncology|2026Cited by 0